Mouse methylome studies SRP246238 Track Settings
 
Disturbed mitochondrial dynamics in CD8+ TIL reinforce epigenetic programming linked with T cell exhaustion [CD8+ intratumoral T cells (in vivo FACS purified cells)]

Track collection: Mouse methylome studies

+  All tracks in this collection (604)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG reads ▾       CpG methylation ▾       PMD       HMR      
Select subtracks by views and experiment:
 All views AMR  CpG reads  CpG methylation  PMD  HMR 
experiment
SRX7654252 
SRX7654253 
SRX7654254 
SRX7654255 
SRX7654257 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX7654252  AMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654252 (AMR)   Schema 
hide
 Configure
 SRX7654252  CpG reads  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654252 (CpG reads)   Schema 
hide
 Configure
 SRX7654252  CpG methylation  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654252 (CpG methylation)   Schema 
hide
 SRX7654252  PMD  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654252 (PMD)   Schema 
hide
 SRX7654252  HMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654252 (HMR)   Schema 
hide
 SRX7654253  AMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654253 (AMR)   Schema 
hide
 Configure
 SRX7654253  CpG reads  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654253 (CpG reads)   Schema 
hide
 Configure
 SRX7654253  CpG methylation  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654253 (CpG methylation)   Schema 
hide
 SRX7654253  PMD  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654253 (PMD)   Schema 
hide
 SRX7654253  HMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654253 (HMR)   Schema 
hide
 SRX7654254  AMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654254 (AMR)   Schema 
hide
 Configure
 SRX7654254  CpG reads  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654254 (CpG reads)   Schema 
hide
 Configure
 SRX7654254  CpG methylation  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654254 (CpG methylation)   Schema 
hide
 SRX7654254  PMD  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654254 (PMD)   Schema 
hide
 SRX7654254  HMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654254 (HMR)   Schema 
hide
 SRX7654255  AMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654255 (AMR)   Schema 
hide
 Configure
 SRX7654255  CpG reads  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654255 (CpG reads)   Schema 
hide
 Configure
 SRX7654255  CpG methylation  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654255 (CpG methylation)   Schema 
hide
 SRX7654255  PMD  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654255 (PMD)   Schema 
hide
 SRX7654255  HMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654255 (HMR)   Schema 
hide
 SRX7654257  AMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654257 (AMR)   Schema 
hide
 Configure
 SRX7654257  CpG reads  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654257 (CpG reads)   Schema 
hide
 Configure
 SRX7654257  CpG methylation  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654257 (CpG methylation)   Schema 
hide
 SRX7654257  PMD  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654257 (PMD)   Schema 
hide
 SRX7654257  HMR  CD8+ intratumoral T cells (in vivo FACS purified cells) / SRX7654257 (HMR)   Schema 
    

Study title: Disturbed mitochondrial dynamics in CD8+ TIL reinforce epigenetic programming linked with T cell exhaustion
SRA: SRP246238
GEO: GSE144583
Pubmed: 33020660

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX7654252 CD8+ intratumoral T cells (in vivo FACS purified cells) 0.739 2.1 26027 1693.6 59 1011.5 147 61070.2 0.984 title: GSM4291231 WGBS_Tumor_Hi_1, Mus musculus, Bisulfite-Seq; {"source_name": "CD8+ T cells", "cell_type": "CD8+ intratumoral T cells (in vivo FACS purified cells)"}
SRX7654253 CD8+ intratumoral T cells (in vivo FACS purified cells) 0.749 2.1 26880 1647.5 36 1006.9 138 59506.2 0.985 title: GSM4291232 WGBS_Tumor_Hi_2, Mus musculus, Bisulfite-Seq; {"source_name": "CD8+ T cells", "cell_type": "CD8+ intratumoral T cells (in vivo FACS purified cells)"}
SRX7654254 CD8+ intratumoral T cells (in vivo FACS purified cells) 0.734 2.1 25611 1749.4 41 940.2 127 59000.6 0.986 title: GSM4291233 WGBS_Tumor_Hi_3, Mus musculus, Bisulfite-Seq; {"source_name": "CD8+ T cells", "cell_type": "CD8+ intratumoral T cells (in vivo FACS purified cells)"}
SRX7654255 CD8+ intratumoral T cells (in vivo FACS purified cells) 0.734 2.2 26708 1702.0 35 1076.8 134 58034.5 0.986 title: GSM4291234 WGBS_Tumor_Hi_4, Mus musculus, Bisulfite-Seq; {"source_name": "CD8+ T cells", "cell_type": "CD8+ intratumoral T cells (in vivo FACS purified cells)"}
SRX7654257 CD8+ intratumoral T cells (in vivo FACS purified cells) 0.725 1.7 24328 1830.7 38 944.3 86 76019.3 0.986 title: GSM4291236 WGBS_Tumor_Lo_6, Mus musculus, Bisulfite-Seq; {"source_name": "CD8+ T cells", "cell_type": "CD8+ intratumoral T cells (in vivo FACS purified cells)"}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.